CSL
CSLLY
Performance
About CSL
CSL is a global biotechnology company composed of CSL Behring, CSL Seqirus, and CSL Vifor, delivering lifesaving medicines and vaccines across more than 100 countries. The company focuses on rare and serious diseases, plasma-derived and recombinant therapies, influenza vaccines, and therapies for iron deficiency and nephrology, with R&D and manufacturing capabilities spanning multiple continents. Since 1916, CSL has combined commercial strength with research-driven innovation to improve patient outcomes worldwide. Its three business units concentrate on plasma/biologics therapy, vaccines, and iron/Kidney health, affirming CSL’s commitment to public health and life-saving care.
Recent News
Top 20 Fastest Growing Pharma & Biotech Companies in the Americas for 2026
ASX Dividend Stocks Paying 7.5%: ELD & AMC
9 Companies Hiring Now in Pennsylvania
CSL Ltd Slashes FY2026 Forecast, Flags $5 B Impairments as Shares Dive 20%
Chiesi to Acquire KalVista for $1.9 B, Adding First Oral HAE Therapy
NICE Update Doubles Eligible Patients for AZ's Lokelma
Kurma Partners Closes €215 Million Biofund IV to Back European BioTech Ventures From Paris
Chiesi Snaps up KalVista for $1.9B, Betting Big on Rare Disease Med Ekterly
CSL Plans $1.5B Expansion of Illinois Plasma Therapy Manufacturing Facility
AYK Energy’s Aries+S System Picked for World’s First Battery-Hybrid Self-Unloader
Havas Pharma Agency Bastion Brands Begins Planned Leadership Succession